Private: Gallery Post #1

13

Feb2023

PMPRB New Chairperson

On Wednesday, February 1, 2023, the Minister of Health announced the appointment of Thomas J Digby as the new Chairperson for the PMPRB. This nomination comes after over a year of being vacant when Dr. Mitchell Levine completed his five-year term tenure on November 2021. Thomas J. Digby ... Read More

13

Feb2023

 pCPA Recruiting Their First CEO

On February 3, 2023, pCPA Office announced a major step in its transition to a stand-alone organization: the recruitment of a chief executive officer (CEO). The new CEO is expected to be in place by Spring 2023. This announcement is a crucial part of the organizational review conducted in ... Read More

20

Dec2022

Updates to the Quebec Guidelines for Drug Submission and Evaluation

The Institut national d’excellence en Santé et en services sociaux (INESSS) has recently updated the Guidance Document for Submitting a Request to INESSS and affiliate documents. This document consolidates updates previously communicated through manufacturer notices and replaces the 2018 version of the guidelines.  ... Read More

19

Dec2022

PMPRB Interim Chairperson Confirms Resignation

Mélanie Bourassa Forcier, Vice-Chairperson and Acting Chairperson of the Patented Medicine Prices Review Board (PMPRB), confirmed her resignation from the Board on Twitter on December 7, 2022. In her comment she indicated she is evaluating her legal obligations concerning whether she can share the reasons for her ... Read More

05

Dec2022

PMPRB’s 2021 Annual Report Shows Worrying Decline in Number of New Medicines Launched in Canada; HDAP Meeting Tentatively Scheduled for Spring 2023

Last week the Patented Medicine Prices Review Board (PMPRB) presented its 2021 Annual Report  to Federal Health Minister Duclos in accordance with its reporting mandate outlined in sections 89 and 100 of the Patent Act. Key statistics reinforce concerns about Canada’s continued attractiveness for new medicine launch ... Read More

05

Dec2022

PDCI Well Wishes for Managing Director Kaitlyn Proulx

PDCI is congratulating its Managing Director, Kaitlyn Proulx, as she begins parental leave effective November 28, 2022.Since joining PDCI in 2010, Kaitlyn has demonstrated incredible strategic insights advising clients on optimizing pricing and market access in Canada. Since becoming Managing Director in 2017, Kaitlyn has ... Read More

05

Dec2022

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More

22

Nov2022

PDCI Launches Sharing Page for PMRPB Consultation on Draft Guidelines- Fall 2022

On October 6, 2022, the Patented Medicine Prices Review Board (PMPRB) published its Draft price regulatory Guidelines and has invited stakeholders to comment on its approach by December 5, 2022. PDCI strives to support timely transparency around public policy consultations and invites organizations and individuals who provided comments to ... Read More

22

Nov2022

CADTH Pharmaceutical Reviews Update Includes Launch of RWE Guidance Consultation

On November 10, 2022, among other procedural updates included in the CADTH Pharmaceutical Reviews Update Issue 32, CADTH published its Real-World Evidence (RWE) Steering Committee’s anticipated Proposed RWE Reporting Guidance and initiated a public consultation on the guidance open now through January 6, 2023.What to know: The ... Read More

13

Oct2022

PDCI’s Early Insights on PMPRB Draft Guidelines

On October 6, 2022, the Patented Medicine Prices Review Board (PMPRB) published its highly anticipated draft price regulatory Guidelines and has invited stakeholders to comment on its approach by December 5, 2022.While some aspects of these guidelines were anticipated, there are a number of new concerns and uncertainties ... Read More